Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 41 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

22%

9 trials in Phase 3/4

Results Transparency

33%

6 of 18 completed with results

Key Signals

6 with results100% success

Data Visualizations

Phase Distribution

35Total
Not Applicable (8)
P 1 (3)
P 2 (15)
P 3 (6)
P 4 (3)

Trial Status

Completed18
Recruiting15
Not Yet Recruiting4
Unknown3
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (41)

Showing 20 of 20 trials
NCT07646678Phase 2RecruitingPrimary

A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia

NCT06812078Phase 2RecruitingPrimary

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

NCT05615584Not ApplicableCompleted

Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence

NCT07500090Phase 3RecruitingPrimary

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)

NCT05668754Phase 2CompletedPrimary

Study of SDX in Patients With Idiopathic Hypersomnia (IH)

NCT06843590Phase 2RecruitingPrimary

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

NCT05371483Enrolling By Invitation

Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments

NCT07625280Phase 3Not Yet Recruiting

A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH

NCT06484348Not ApplicableRecruiting

Deciphering the Interactions Between Food Intake, Sleepiness, and Nighttime Sleep Quality in Patients With Type 1 Narcolepsy and Idiopathic Hypersomnia

NCT05837091Phase 4RecruitingPrimary

Low Sodium Oxybate in Patients With Idiopathic Hypersomnia

NCT06525077Phase 3CompletedPrimary

Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)

NCT06752668Phase 2Recruiting

A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

NCT07096674Phase 2Recruiting

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

NCT06251063Not ApplicableCompleted

Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence

NCT06767683Phase 2Recruiting

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

NCT05458128Phase 3CompletedPrimary

A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia

NCT07006233Not ApplicableRecruitingPrimary

A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia

NCT06252571Phase 2RecruitingPrimary

a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial

NCT07077278Phase 4Not Yet RecruitingPrimary

Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome

NCT05875974Phase 4CompletedPrimary

A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy

Scroll to load more

Research Network

Activity Timeline